Landos Biopharma Inc (LABP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,935 | -39,276 | -38,422 | -30,144 | -13,467 |
| Depreciation Amortization | 44 | 1,727 | 1,370 | 137 | 103 |
| Accounts payable and accrued liabilities | -2,129 | -9,473 | 4,263 | 6,506 | 415 |
| Other Working Capital | 443 | -10,074 | 5,891 | 5,881 | 3,277 |
| Other Operating Activity | 3,100 | 11,325 | -163 | -5,342 | -202 |
| Operating Cash Flow | $-20,477 | $-45,771 | $-27,061 | $-22,962 | $-9,874 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 229 | -440 | -181 | -158 |
| Purchase Of Investment | N/A | -3,671 | -174,853 | -21,718 | -40,319 |
| Sale Of Investment | 7,775 | 77,502 | 116,587 | 36,030 | 152 |
| Investing Cash Flow | $7,775 | $74,060 | $-58,706 | $14,131 | $-40,325 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 7,980 |
| Common Stock Issued | 16,567 | N/A | 93,514 | 1,518 | N/A |
| Common Stock Repurchased | -3,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | -1,907 | 0 | 51,668 |
| Financing Cash Flow | $13,567 | $N/A | $91,607 | $1,518 | $59,648 |
| Exchange Rate Effect | 44 | 46 | 49 | -79 | N/A |
| Beginning Cash Position | 36,640 | 8,305 | 2,416 | 9,808 | 359 |
| End Cash Position | 37,549 | 36,640 | 8,305 | 2,416 | 9,808 |
| Net Cash Flow | $909 | $28,335 | $5,889 | $-7,392 | $9,449 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,477 | -45,771 | -27,061 | -22,962 | -9,874 |
| Capital Expenditure | N/A | -7 | -440 | -181 | -158 |
| Free Cash Flow | -20,477 | -45,778 | -27,501 | -23,143 | -10,032 |